VivoSeq
Other

Hip Arthroplasty

0

Pipeline Programs

4

Active Trials

0

Companies Involved

Hip Arthroplasty is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

16/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

19

clinical trials

Completed12 · 63%
Recruiting3 · 16%
Withdrawn2 · 11%
Terminated1 · 5%
Not yet recruiting1 · 5%

Trial Activity

19 trials

TXA vs. Amicar in Total Knee and Hip Arthroplasty
Completed··Phase 4·NCT02030821·246 enrolled
Pre-emptive Dexamethasone in Hip Arthroplasty
Completed·TTanta University·N/A·NCT04898920·83 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)